全文获取类型
收费全文 | 632篇 |
免费 | 35篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 1篇 |
基础医学 | 41篇 |
口腔科学 | 1篇 |
临床医学 | 20篇 |
内科学 | 166篇 |
皮肤病学 | 83篇 |
神经病学 | 8篇 |
特种医学 | 20篇 |
外科学 | 57篇 |
综合类 | 13篇 |
预防医学 | 7篇 |
眼科学 | 6篇 |
药学 | 11篇 |
肿瘤学 | 229篇 |
出版年
2023年 | 9篇 |
2022年 | 8篇 |
2021年 | 15篇 |
2020年 | 7篇 |
2019年 | 14篇 |
2018年 | 25篇 |
2017年 | 16篇 |
2016年 | 21篇 |
2015年 | 18篇 |
2014年 | 16篇 |
2013年 | 19篇 |
2012年 | 52篇 |
2011年 | 45篇 |
2010年 | 36篇 |
2009年 | 17篇 |
2008年 | 36篇 |
2007年 | 37篇 |
2006年 | 40篇 |
2005年 | 33篇 |
2004年 | 28篇 |
2003年 | 18篇 |
2002年 | 39篇 |
2001年 | 16篇 |
2000年 | 15篇 |
1999年 | 8篇 |
1998年 | 5篇 |
1997年 | 6篇 |
1996年 | 7篇 |
1995年 | 1篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1988年 | 8篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1947年 | 1篇 |
排序方式: 共有668条查询结果,搜索用时 0 毫秒
31.
Plasma ghrelin and desacyl ghrelin concentrations in renal failure 总被引:11,自引:0,他引:11
Yoshimoto A Mori K Sugawara A Mukoyama M Yahata K Suganami T Takaya K Hosoda H Kojima M Kangawa K Nakao K 《Journal of the American Society of Nephrology : JASN》2002,13(11):2748-2752
Ghrelin is a novel hormone that possesses growth hormone (GH)-releasing, cardiovascular, and metabolic activities. Ghrelin is a unique acylated polypeptide, and the naked peptide, desacyl ghrelin, does not have the activity. This study examines plasma ghrelin concentrations in 41 patients with mild to severe renal diseases. Two kinds of radioimmunoassays were used: amino-terminal immunoreactivity represents ghrelin alone (N-IR), and carboxyl-terminal immunoreactivity corresponds to the sum of both ghrelin and desacyl ghrelin (C-IR). In all subjects, the plasma N-IR was much smaller than the C-IR, indicating that desacyl ghrelin predominates over ghrelin in the circulation. The plasma C-IR, but not N-IR, was significantly correlated with the serum creatinine level and was increased 2.8-fold in patients with end-stage renal disease compared with those in patients with normal renal function. The plasma GH concentration was significantly correlated with the plasma N-IR and the C-IR, as well as with the serum creatinine level. Bilateral nephrectomy in mice caused marked increase in the plasma C-IR without significant changes in the local C-IR and ghrelin mRNA level in the stomach, which is the main site of ghrelin production. These findings suggest that circulating ghrelin concentrations play a role in the regulation of blood GH concentrations and that the kidney is an important site for clearance and/or degradation of desacyl ghrelin. Furthermore, elevation of blood GH levels in renal failure seems to be caused by a mechanism other than alteration in the circulating ghrelin concentration. 相似文献
32.
Kensei Yamaguchi Tomotaka Shimamura Yoshito Komatsu Akinori Takagane Takashi Yoshioka Soh Saitoh Masaki Munakata Yu Sakata Tsukasa Sato Tatsuhiro Arai Hiroshi Saitoh 《Gastric cancer》2006,9(1):36-43
Background Both paclitaxel (TXL) and cisplatin (CDDP) show efficacy against gastric cancer. The aim of this phase I-II study was to determine
the maximum tolerated dose (MTD) and to evaluate the toxicity and efficacy of combination chemotherapy with these two agents.
Methods Nineteen patients entered the phase I part of the study, and 21 patients entered the phase II part. TXL infusions were administered
on days 1 and 15, with a fixed 3mg/m2 dose of CDDP.
Results In the phase I part of the study, we determined dose level 5, which represented a TXL dose of 18mg/m2, with CDDP 3mg/m2, to be the MTD. The recommended dose (RD) was level 4, with a TXL dose of 16mg/m2 with CDDP, 3mg/m2. In the phase II part of the study, the response rate was 25.0%; five patients had a partial response, seven had stable disease,
6 had progressive disease, and 2 were not evaluable. Grade 3 or 4 neutropenia was the most common adverse event and occurred
in 65% of the patients. During treatment, 25% of the patients received granulocyte colony-stimulating factor, but febrile
neutropenia was not shown in any of the patients. Major nonhematological toxicities were nausea/vomiting, anorexia, fatigue,
alopecia, and sensory neuropathy. Adverse reactions of grade 3 or 4 were shown by two patients, one with anorexia (5%) and
the other with sensory neuropathy (5%).
Conclusion The RD was determined to be TXL 14mg/m2, with CDDP 3mg/m2. 相似文献
33.
Takeshi Saito Yoshinobu Kanda Masahiro Kami Kazunori Kato Nahoko Shoji Sachiyo Kanai Toshihiro Ohnishi Yoshifumi Kawano Kunihisa Nakai Toshie Ogasawara Hiroshi Matsubara Atsushi Makimoto Ryuji Tanosaki Kensei Tobinai Hiro Wakasugi Yoichi Takaue Shin Mineishi 《Clinical cancer research》2002,8(4):1014-1020
PURPOSE: Cladribine (2-CdA) is a purine analogue that exhibits activity against a variety of hematological malignancies and has a potent immunosuppressive effect. We therefore performed a pilot study to evaluate the feasibility of a novel 2-CdA-based reduced-intensity stem cell transplantation (RIST) regimen. EXPERIMENTAL DESIGN: A total of 16 scheduled patients with hematological malignancies were enrolled for comparison of their data with conventional stem cell transplantation (n = 19). The regimen for RIST consisted of 2-CdA (0.11 mg/kg/day for 6 days), busulfan (4 mg/kg/day for 2 days), and rabbit antithymocyte globulin (2.5 mg/kg/day for 4, 2, or 0 days). The underlying diseases included acute myelogenous leukemia (n = 6), chronic myelogenous leukemia (n = 2), myelodysplastic syndrome (n = 6), and non-Hodgkin's lymphoma (n = 2). RESULTS: After RIST, four patients died before day 100 as a result of acute graft-versus-host disease (n = 1), bacteremia (n = 1), disseminated candidasis (n = 1) and congestive heart failure (n = 1). Another patient died of cerebral infarction on day 140. Thus, acute-phase regimen-related toxicities >grade III were observed in only one patient. Engraftment and complete donor chimerism were achieved by day 28 in 14 evaluable patients, and 6 of them (43%) experienced grade II-IV acute graft-versus-host disease. With a median follow-up of 328 days (range, 231-633 days), the actuarial 1-year overall and disease-free survival rates were 69% and 50%, respectively. Notably, among seven high-risk patients (five patients had been in complete remission two or more times and two not in complete remission with refractory disease at transplant), only two patients developed leukemia relapse after RIST. Although the recovery of CD4+ cells was significantly slower (P = 0.02) in RIST than in conventional stem cell transplantation, the incidence of clinically documented infections was not significantly different between the two groups. CONCLUSION: The results suggest that this novel regimen containing 2-CdA is well tolerated and induces early complete donor chimerism. The unexpected durable remission achieved in patients with advanced disease at transplant suggests the presence of an acceptable antileukemia/lymphoma effect, which would warrant a further clinical trial. 相似文献
34.
K Itoh T Ohtsu H Fukuda Y Sasaki M Ogura Y Morishima T Chou K Aikawa N Uike F Mizorogi T Ohno S Ikeda T Sai M Taniwaki F Kawano M Niimi T Hotta M Shimoyama K Tobinai 《Annals of oncology》2002,13(9):1347-1355
BACKGROUND: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is accepted as the best available standard treatment for first-line chemotherapy in aggressive non-Hodgkin's lymphoma (NHL). However, the therapeutic efficacy of CHOP remains unsatisfactory, particularly in high-intermediate risk and high risk patients, and a new strategy is warranted in this patient population. The aim of the present study was to explore a suitable therapeutic-intensified regimen for the treatment of aggressive NHL. PATIENTS AND METHODS: Between May 1995 and July 1998, a total of 70 patients with high-intermediate risk or high risk aggressive NHL, according to the International Prognostic Index, were enrolled and randomly assigned to receive either eight cycles of standard CHOP (cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) and prednisolone 100 mg for 5 days) every 2 weeks, or six cycles of dose-escalated CHOP (cyclophosphamide 1500 mg/m(2), doxorubicin 70 mg/m(2), vincristine 1.4 mg/m(2) and prednisolone 100 mg for 5 days) every 3 weeks. Lenograstim (glycosylated rHuG-CSF), at a dose of 2 micro g/kg/day s.c., was administered daily from day 3 until day 13 with biweekly CHOP and until day 20 with the dose-escalated CHOP. The primary endpoint was complete response rate. RESULTS: The complete response rate was 60% [21 of 35; 95% confidence interval (CI) 42% to 76%] with biweekly CHOP and 51% (18 of 35; 95% CI 34% to 69%) with dose-escalated CHOP. The major toxicity was grade 4 neutropenia and was more frequent in the dose-escalated CHOP arm (86%) than in the biweekly CHOP arm (50%). Grade 4 thrombocytopenia was also more frequent in the dose-escalated CHOP arm (20%) than the biweekly CHOP arm (3%). Non-hematological toxicities were acceptable in both arms. One treatment-related death (due to cardiac arrhythmia) was observed in a dose-escalated CHOP patient. Progression-free survival at 3 years was 43% (95% CI 27% to 59%) in the biweekly CHOP arm and 31% (95% CI 16% to 47%) in the dose-escalated CHOP arm. Although seven patients were deemed ineligible by central review of the pathological diagnosis, the results for both eligible and all enrolled patients were similar. CONCLUSIONS: Similar complete response rates and progression-free survival rates, but lower toxicity, indicated that biweekly CHOP was superior to dose-escalated CHOP in the treatment of aggressive NHL. Based on these results, the Lymphoma Study Group of the Japan Clinical Oncology Group is conducting a randomized phase III study comparing biweekly CHOP with standard CHOP in newly diagnosed patients with advanced-stage aggressive NHL. 相似文献
35.
Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group 总被引:1,自引:0,他引:1
Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y 《Japanese journal of clinical oncology》1997,27(3):146-153
Cladribine (2-chlorodeoxyadenosine;) is a purine analogue with clinical
activity against hairy cell leukemia, chronic lymphocytic leukemia and
indolent lymphoma. To clarify the toxicity profiles of cladribine, we
conducted a phase I and pharmacological study of cladribine with a schedule
of seven-day continuous intravenous infusion every 28 days up to a maximum
of three cycles. We enrolled 10 previously-treated patients with various
lymphoid malignancies. No dose-limiting toxicity (grade 4 hematologic
and/or grade 3 or more non-hematologic) was observed in the three patients
who received 0.06 mg/kg/day (Level 1). Of the seven patients who received
0.09 mg/kg/day (Level 2), one patient developed grade 4 hypoxemia and grade
4 thrombocytopenia, and another developed grade 4 neutropenia. Of the seven
patients treated at Level 2, one with cutaneous T-cell lymphoma attained
complete remission, and one with mantle cell lymphoma, one with chronic
lymphocytic leukemia and one with adult T-cell leukemia-lymphoma attained
partial remission. A pharmacokinetic analysis of the seven patients without
leukemic cells showed that their area under the concentration versus time
curves of plasma cladribine increased dose-dependently from 2661.3 +/-
300.4 nM x h at Level 1 (n = 3) to 3411.3 +/- 341.0 nM x h at Level 2 (n =
4) (P = 0.034). We conclude that the recommended phase II dose of
cladribine (0.09 mg/kg/day as a seven-day continuous i.v. infusion) in
Caucasian patients can be safely administered to Japanese patients. The
encouraging results prompted us to plan subsequent phase II studies of
cladribine against adult T-cell leukemia-lymphoma, hairy cell leukemia and
indolent lymphoma.
相似文献
36.
Ishikura S Tobinai K Ohtsu A Nakamura S Yoshino T Oda I Takagi T Mera K Kagami Y Itoh K Tamaki Y Suzumiya J Taniwaki M Yamamoto S 《Cancer science》2005,96(6):349-352
CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) followed by radiotherapy is regarded as standard care for localized aggressive lymphoma; however, prospective confirmation of its applicability to localized primary gastric lymphoma is inadequate, and most patients in Japan have been initially treated with gastrectomy. We conducted a multicenter phase II study to evaluate the feasibility and efficacy of the non-surgical treatment. Eligibility criteria required primary gastric diffuse large B-cell lymphoma, stage I-II(1), age 20-75, performance status 0-1 and adequate organ function. Treatment consisted of three cycles of CHOP followed by radiotherapy 40.5 Gy. Fifty-five patients were enrolled between December 1999 and February 2003, and 52 eligible patients were analyzed. Patient characteristics were as follows: median age, 61 years; 28 men, 24 women; 36 with stage I, 16 with stage II(1); 47 with a low International Prognostic Index (IPI) and five with a low-intermediate IPI. All but one patient completed planned treatment. No serious complications including massive hemorrhage or perforation were observed. A complete response was achieved in 48 of the 52 patients (92%, 95% confidence interval: 82-98%) and progressive disease in three. Two patients underwent salvage gastrectomy due to disease persistence or recurrence. With a median follow-up period of 28 months, 2-year progression-free and overall survivals were 88 and 94%, respectively. CHOP followed by radiotherapy is safe and highly effective in localized gastric diffuse large B-cell lymphoma. This organ-preserving treatment should be considered as a very reasonable therapeutic option. 相似文献
37.
38.
Soejima T Murakami H Inoue T Kanazawa T Katouda M Nagata K 《The Kurume medical journal》2005,52(4):127-131
To investigate the direct effect to the cartilage caused by the meniscal repair, we examined patients who underwent an isolated meniscal repair without any other abnormalities by arthroscopic examination. A total of 17 patients were examined by second-look arthroscopy after an average interval of 9 months from the meniscal repair, and have been evaluated the status of the repaired meniscus and of the relative femoral condylar cartilage. Changes in the severity of the cartilage lesion between at the time of meniscal repair and the time of the second-look arthroscopy were considered based on the status of the repaired meniscus. Regardless of the healing status of the repair site, it was possible to prevent degeneration in the cartilage in 9 of the 10 patients who demonstrated no degeneration in the meniscal body. Of the 7 patients who demonstrated degeneration in the meniscal body, progression in cartilage degeneration was noted as 1 grade in 2 patients and 2 grades in another 3 patients. Even in those in which stable fusion of the repair site was achieved, the condition of the inner meniscal body was not necessarily maintained favorably in all cases, indicating that degeneration in the meniscal body was a risk factor for cartilage degeneration. It was concluded that recovery could not be expected even at 9 months after the repair if the lesion had already demonstrated degeneration in the meniscal body at the time of repair. 相似文献
39.
Kusumoto S Kobayashi Y Sekiguchi N Tanimoto K Onishi Y Yokota Y Watanabe T Maeshima AM Ishida T Inagaki H Matsuno Y Ueda R Tobinai K 《The American journal of surgical pathology》2005,29(8):1067-1073
Amplification and translocation of the Bcl-2 gene has been detected in a certain subset of diffuse large B-cell lymphomas (DLBCL). The correlations among Bcl-2 protein expression, gene translocation or amplification, and the molecular signature determined by cDNA array are poorly understood. This study examined 25 cases with de novo nodal DLBCL. Interphase fluorescence in situ hybridization (FISH) analysis was performed to evaluate the Bcl-2 gene using IGH/BCL2 and CEP18 centromere probes (Vysis). When extra Bcl-2 gene signals were observed in each tumor cell and when these signals were in proportion to the extra CEP18 probe signals, we regarded the findings as indicating the presence of an additional chromosome 18; when extra Bcl-2 signals were observed but additional CEP18 signals were not, we regarded the findings as indicating the presence of gene amplification. A panel of 3 antigens (CD10, Bcl-6, and MUM-1) was applied to categorize each case as either a "germinal center B-cell (GCB) phenotype" or a "non-GCB phenotype." Of the 25 cases examined, 8 cases (32%) were classified as "GCB phenotype" and 17 cases (68%) were classified as "non-GCB phenotype." A FISH analysis revealed that t(14;18) was detected in 2 of the 8 cases (25%) with the "GCB phenotype" but in none of the 17 "non-GCB phenotype" cases. Extra Bcl-2 gene signals were detected in 7 of the 25 (28%) cases examined: n = 5 for an additional chromosome 18, n = 1 for gene amplification, and n = 1 for additional chromosome 18 + gene amplification. Extra Bcl-2 gene signals were exclusively detected in DLBCL with the "non-GCB phenotype"; these cases, with the exception of one, stained strongly positive for Bcl-2. The DLBCLs with Bcl-2 protein overexpression were classified into at least two heterogeneous molecular groups, based on the results of the FISH analysis. 相似文献
40.